Madej R
Roche Molecular Systems, Inc, Pleasanton, CA, USA.
Mol Diagn. 2001 Dec;6(4):335-45. doi: 10.1054/modi.2001.29159.
Ten years ago, laboratory directors introducing molecular infectious disease diagnostics in the routine clinical setting had few resources to assist in their implementation and quality assurance programs. In the past 10 years, several organizations have recognized this need and have established standard reference materials, controls, external quality assessment programs, and written guidelines. It is a challenge for the clinical laboratory scientist to evaluate and incorporate these new programs and services in the context of traditional good laboratory practice and current laboratory regulations. This article presents many of the options available for control materials, proficiency programs, standard reference materials, and written guidelines. It shows where harmonization of new practice with long-standing convention and regulation is progressing and where questions remain.
十年前,在常规临床环境中引入分子传染病诊断技术的实验室主任几乎没有资源来协助他们开展实施工作和质量保证计划。在过去十年里,一些组织已经认识到这一需求,并建立了标准参考物质、对照品、外部质量评估计划和书面指南。对于临床实验室科学家而言,在传统的良好实验室规范和现行实验室法规的背景下评估并纳入这些新计划和服务是一项挑战。本文介绍了许多可用于对照材料、能力验证计划、标准参考物质和书面指南的选项。它展示了新实践与长期惯例和法规的协调在哪些方面取得了进展,以及哪些方面仍然存在问题。